Silver nanoparticles alter the dimerization of Aβ42 studied by REMD simulations

Quynh Mai Thai1,2, Phuong-Thao Tran3, Huong T T Phung4

  • 1Laboratory of Biophysics, Institute of Advanced Study in Technology, Ton Duc Thang University Ho Chi Minh City Vietnam ngosontung@tdtu.edu.vn.

RSC Advances
|May 9, 2024
PubMed

Insights

Silver nanoparticles may inhibit amyloid beta (Aβ) oligomerization, a key process in Alzheimer

Area of Science:

  • Biochemistry
  • Neuroscience
  • Materials Science

Background:

  • Amyloid beta (Aβ) peptide aggregation is linked to Alzheimer's disease (AD).
  • Aβ oligomerization in various environments contributes to neurotoxicity in AD patients.
  • Developing effective inhibitors for neurotoxic Aβ forms is crucial for AD treatment.

Purpose of the Study:

  • To investigate the influence of silver nanoparticles on Aβ peptide oligomerization.
  • To understand the mechanisms by which silver nanoparticles affect Aβ aggregation.
  • To explore Aβ inhibitor pathways for potential AD therapeutic strategies.

Main Methods:

  • Temperature replica-exchange molecular dynamics (REMD) simulations were employed.
  • Oligomerization of dimeric Aβ peptides was studied with and without silver nanoparticles.
  • Analysis included intermolecular contact maps and free energy landscapes.

Main Results:

  • Silver nanoparticles alter the oligomerization process of dimeric Aβ peptides.
  • Specific metrics show differences in Aβ aggregation in the presence of silver nanoparticles.
  • Insights into the physical mechanisms influencing Aβ oligomerization were obtained.

Conclusions:

  • Silver nanoparticles show potential as inhibitors of Aβ oligomerization.
  • Understanding nanoparticle interactions with Aβ is vital for developing AD therapies.
  • This study provides a basis for exploring Aβ inhibitor pathways.

Related Concept Videos